Jul 15, 2021 / 05:00PM GMT
Raj Prasad - William Blair & Company LLC - Analyst
I am Raj Prasad. I am on the biotech team here at William Blair, and I cover Beam Therapeutics. Before we begin, I just have to tell you, for a list of disclosures or conflicts of interest, see our website at williamblair.com. And with that, glad to have you, John. Lots of things going on at Beam.
So maybe just to start and provide a foundation for the conversation, a brief overview of the Company and of base editing technology and where it has come from and where it is now.
John Evans - Beam Therapeutics Inc. - CEO and Board Member
Great. Yes. Thanks for having us, excited to see you again.
So Beam was founded to be focusing on next-generation technology within gene editing, specifically initially called base editing. So we were founded in 2017 by leaders in the CRISPR field, so this is David Liu, Feng Zhang and Keith Joung.
And stepping back, if you think about where the CRISPR field comes from: so gene editing, we have zinc fingers; we have TALENs; and then of course CRISPR
Beam Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers